Jing Tian1, Tienju Wang1, Kun Jia1, Lan Guo2, Russell H Swerdlow3, Heng Du1,2,3. 1. Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA. 2. Higuchi Biosciences Center, University of Kansas, Lawrence, KS, USA. 3. Department of Neurology, Alzheimer's Disease Center University of Kansas Medical Center, Lawrence, KS, USA.
Abstract
BACKGROUND: Metabolic dysfunction links to cognitive deficits in Alzheimer's disease (AD). Leptin is an anti-obesity hormone that modulates energy homeostasis and memory function. Although leptin deregulation is implicated in mouse models of AD-like brain pathology, clinical studies have shown inconsistent results regarding an association of leptin with the development of this neurodegenerative disorder. OBJECTIVE: We investigated the changes of plasma leptin and the correlation of sex-stratified circulating leptin with cognitive performance, AD-related biological markers, and metabolic status in patients with AD and cognitively unimpaired (CU) counterparts. METHODS: We used nonobese AD patients and CU controls in a University of Kansas Medical Center (KUMC) cohort. Plasma leptin levels, circulating AD-related molecules and metabolic profiles were examined and analyzed. RESULTS: In contrast to unchanged circulating leptin in females, male patients exhibited decreased plasma leptin levels compared with male CU counterparts. Moreover, plasma leptin showed no correlation with cognitive performance and AD blood biomarkers in patients with either sex. Of note, females but not males demonstrated an association of plasma leptin with body mass index, high density lipoprotein-cholesterol and its ratio with total cholesterol and triglycerides. CONCLUSION: Our findings suggest that leptin deficiency is associated with nonobese male AD patients, supporting systemic dysmetabolism in the development of this neurodegenerative disorder in certain populations. Although plasma leptin may have limited capacity to reflect disease severity or progression, future mechanistic studies on the regulation of leptin in nonobese patients with AD would deepen our understanding of the sex-related disparity of AD etiopathogenesis.
BACKGROUND: Metabolic dysfunction links to cognitive deficits in Alzheimer's disease (AD). Leptin is an anti-obesity hormone that modulates energy homeostasis and memory function. Although leptin deregulation is implicated in mouse models of AD-like brain pathology, clinical studies have shown inconsistent results regarding an association of leptin with the development of this neurodegenerative disorder. OBJECTIVE: We investigated the changes of plasma leptin and the correlation of sex-stratified circulating leptin with cognitive performance, AD-related biological markers, and metabolic status in patients with AD and cognitively unimpaired (CU) counterparts. METHODS: We used nonobese AD patients and CU controls in a University of Kansas Medical Center (KUMC) cohort. Plasma leptin levels, circulating AD-related molecules and metabolic profiles were examined and analyzed. RESULTS: In contrast to unchanged circulating leptin in females, male patients exhibited decreased plasma leptin levels compared with male CU counterparts. Moreover, plasma leptin showed no correlation with cognitive performance and AD blood biomarkers in patients with either sex. Of note, females but not males demonstrated an association of plasma leptin with body mass index, high density lipoprotein-cholesterol and its ratio with total cholesterol and triglycerides. CONCLUSION: Our findings suggest that leptin deficiency is associated with nonobese male AD patients, supporting systemic dysmetabolism in the development of this neurodegenerative disorder in certain populations. Although plasma leptin may have limited capacity to reflect disease severity or progression, future mechanistic studies on the regulation of leptin in nonobese patients with AD would deepen our understanding of the sex-related disparity of AD etiopathogenesis.
Entities:
Keywords:
Alzheimer’s disease; blood biomarker; metabolism; plasma leptin; sex
Authors: M S Hickey; R G Israel; S N Gardiner; R V Considine; M R McCammon; G L Tyndall; J A Houmard; R H Marks; J F Caro Journal: Biochem Mol Med Date: 1996-10
Authors: Jane M Johnston; William T Hu; David W Fardo; Steven J Greco; George Perry; Thomas J Montine; John Q Trojanowski; Leslie M Shaw; J Wesson Ashford; Nikolaos Tezapsidis Journal: Curr Alzheimer Res Date: 2014-02 Impact factor: 3.498
Authors: Na Zhao; Yingxue Ren; Yu Yamazaki; Wenhui Qiao; Fuyao Li; Lindsey M Felton; Siamak Mahmoudiandehkordi; Alexandra Kueider-Paisley; Berkiye Sonoustoun; Matthias Arnold; Francis Shue; Jiaying Zheng; Olivia N Attrebi; Yuka A Martens; Zonghua Li; Ligia Bastea; Axel D Meneses; Kai Chen; J Will Thompson; Lisa St John-Williams; Masaya Tachibana; Tomonori Aikawa; Hiroshi Oue; Lucy Job; Akari Yamazaki; Chia-Chen Liu; Peter Storz; Yan W Asmann; Nilüfer Ertekin-Taner; Takahisa Kanekiyo; Rima Kaddurah-Daouk; Guojun Bu Journal: Neuron Date: 2020-03-20 Impact factor: 18.688
Authors: Thomas J Littlejohns; Katarina Kos; William E Henley; Antonio Cherubini; Luigi Ferrucci; Iain A Lang; Kenneth M Langa; David Melzer; David J Llewellyn Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472